Drug therapy for chronic thromboembolic pulmonary hypertension : a review of the comparative clinical effectiveness / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author.

Series:

Rapid response report.

Rapid response report, summary with critical appraisal

Language:

English

Subjects (All):

Pulmonary hypertension--Chemotherapy.

Pulmonary hypertension.

Thromboembolism--Chemotherapy.

Thromboembolism.

Hypertension, Pulmonary--drug therapy.

Thromboembolism--drug therapy.

Medical Subjects:

Hypertension, Pulmonary--drug therapy.

Thromboembolism--drug therapy.

Physical Description:

1 online resource (19 pages)

Other Title:

Drug therapy for chronic thromboembolic pulmonary hypertension

Place of Publication:

Ottawa : Canadian Agency for Drugs and Technologies in Health, 2014.

Summary:

Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease which results from incomplete resolution of the vascular obstruction caused by pulmonary thromboembolism. Pulmonary endarterectomy (PEA) is the first choice treatment for patients with proximal CTEPH. However, PEA is not an option when occlusion occurs in distal vessels not surgically accessible, or when patients have comorbidities that preclude the intervention. Riociguat, a soluble guanylate cyclase stimulator (sGC), is currently the only drug with Health Canada approved indication for the management of inoperable CTEPH or persistent or recurrent CTEPH after surgical treatment in adults 18 years or older with PH of World Health Organization (WHO) functional class II or III. The WHO functional class ranges from I to IV, with higher numbers indicating greater functional limitations. Since histopathology studies suggest that CTEPH and primary pulmonary artery hypertension (PAH) share common pathways in their pathophysiology and manifest similar small-vessel changes, vasoactive therapies with evidence of efficacy in PAH are commonly prescribed off-label for CTEPH patients who require medical intervention. In Canada, specific therapies for PAH include sGC stimulators, endothelin receptor antagonists (ERA), phosphodiesterase-5 inhibitors (PDE-5), and prostacyclin analogues. The objective of this report is to review current evidence of comparative efficacy and safety of monotherapy or combination therapy of medical interventions for patients with CTEPH.

Notes:

Description based on publisher supplied metadata and other sources.

"9 September 2014".

Includes bibliographical references (page 12).

OCLC:

898100169

Publisher Number:

244480 CaOOCEL (Public Documents)